Table 1.
Baseline demographic, clinical, and laboratory values in total and according to the tertiles of soluble endotoxin receptor CD14 in 310 maintenance hemodialysis patients 1
| Variable | Tertiles of soluble endotoxin receptor CD14
|
|||
|---|---|---|---|---|
| Tertile 1 <6 (n= 103) |
Tertile 2 6 to 7.84 (n= 104) |
Tertile 3 >7.84 (n= 103) |
P for trend | |
| Demographic | ||||
| Age (years) | 52.7±14.9 | 56.2±14.2 | 56.4±14.9 | 0.08 |
| Women (%) | 52 | 47 | 46 | 0.4 |
| Race: % African-American | 32 | 20 | 37 | 0.5 |
| Ethnicity: % Hispanic | 48 | 63 | 46 | 0.8 |
| Primary insurance: % Medicare | 49 | 55 | 52 | 0.7 |
| Diabetes mellitus (%) | 58 | 63 | 50 | 0.2 |
| Modified Charlson comorbidity score | 1.2±1.2 | 1.7±1.5 | 2.2±1.6 | 0.8 |
| Crude mortality rate (%)3 | 14 | 22 | 33 | 0.001 |
| Body composition | ||||
| Body mass index (kg/m2) | 27.1±7.3 | 26.3±5.9 | 24.9±5.1 | 0.01 |
| Triceps skinfold (mm) | 19.6±11.4 | 17.2±9.9 | 13.9±7.8 | <0.001 |
| Biceps skinfold (mm) | 10.3±8.1 | 9.4±7.3 | 7.9±6.0 | 0.02 |
| Mid-arm circumference (cm) | 31.8±6.4 | 31.0±5.7 | 29.6±5.3 | 0.01 |
| Near infrared measured body fat (%) | 28.4±10.9 | 28.1±10.6 | 25.7±10.6 | 0.08 |
| Hemodialysis treatment measures | ||||
| Dialysis vintage (months) | 43.8±34.3 | 51.9±35.3 | 54.4±35.3 | 0.006 |
| Dialysis dose (Kt/V single pool) | 1.67±0.29 | 1.71±0.30 | 1.71±0.25 | 0.3 |
| nPNA (nPCR) (g.kg−1.day−1) | 1.10±0.22 | 1.10±0.28 | 1.07±0.24 | 0.3 |
| Erythropoietin dose (1,000 u/week) | 15.0±16.2 | 12.7±10.3 | 15.1±15.5 | 0.6 |
| Biochemical measurements | ||||
| Serum albumin (g/dl) | 4.0±0.3 | 4.0±0.4 | 3.9±0.4 | 0.05 |
| prealbumin (transthyretin) (mg/dl) | 30.3±8.4 | 29.4±8.9 | 28.3±8.3 | 0.1 |
| creatinine (mg/dl) | 10.3±2.7 | 9.6±2.7 | 9.9±2.8 | 0.3 |
| total iron binding capacity (mg/dl) | 213±35 | 208±37 | 198±33 | 0.003 |
| calcium (mg/dl) | 9.7±0.7 | 9.6±0.6 | 9.6±0.6 | 0.2 |
| phosphorus (mg/dl) | 5.7±1.2 | 5.4±1.3 | 5.6±1.5 | 0.4 |
| Alkaline phosphatase (U/L) | 115±56 | 126±66 | 140±102 | 0.02 |
| iron saturation ratio | 33.3±10.4 | 35.0±12.1 | 35.0±12.5 | 0.3 |
| ferritin (ng/ml) | 500±332 | 656±422 | 728±353 | <0.001 |
| total homocysteine (μmol/l) | 24.2±7.1 | 25.5±8.1 | 27.2±8.8 | 0.008 |
| LDL-C | 75.6±30.2 | 78.9±31.1 | 83.3±35.4 | 0.1 |
| HDL-C | 39.1±13.1 | 35.5±12.8 | 35.2±12.4 | 0.04 |
| total cholesterol | 142±40 | 148±41 | 147±47 | 0.4 |
| triglycerides | 141±108 | 176±165 | 143±92 | 0.9 |
| C-reactive protein (mg/l) | 4.1±5.1 | 4.9±5.4 | 5.8±6.2 | 0.01 |
| IL-6 (pg/ml) | 8.8±12.5 | 9.7±10.3 | 13.0±16.9 | 0.006 |
| TNF-α (pg/ml) | 2.2±0.8 | 2.5±0.8 | 2.8±1.2 | <0.001 |
| Blood hemoglobin (g/dl) | 12.2±0.8 | 12.1±0.8 | 12.1±0.9 | 0.5 |
| WBC (×1000 cell/μl) | 7.0±2.2 | 6.9±1.7 | 6.7±2.0 | 0.3 |
| lymphocyte (% of total WBC) | 23.8±8.1 | 23.4±6.5 | 23.5±8.1 | 0.7 |
1
Kt/V, dialysis dose; nPCR, normalized protein catabolic rate; IL-6, Interleukin 6; TNF-α, Tumor necrosis factor α; LDL, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol
2
All values are presented as mean ± SD or percentages
3
Mortality pertains to maximum of 33 months
*
P-values for dialysis dose (vintage), ferritin, vitamin D dose, CRP, IL-6, and TNF- α are based on the logarithmic values of these measures.